{
    "id": 26190,
    "fullName": "CDKN2A negative",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "CDKN2A negative indicates a lack of the CDKN2A gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1029,
        "geneSymbol": "CDKN2A",
        "terms": [
            "CDKN2A",
            "ARF",
            "CDK4I",
            "CDKN2",
            "CMM2",
            "INK4",
            "INK4A",
            "MLM",
            "MTS-1",
            "MTS1",
            "P14",
            "P14ARF",
            "P16",
            "P16-INK4A",
            "P16INK4",
            "P16INK4A",
            "P19",
            "P19ARF",
            "TP16"
        ]
    },
    "variant": "negative",
    "createDate": "03/29/2017",
    "updateDate": "08/24/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16761,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and PF-04691502 synergisticaly inhibited growth of Cdkn2a-null non-small cell lung cancer cell lines in culture (PMID: 30647837).",
            "molecularProfile": {
                "id": 27380,
                "profileName": "CDKN2A negative"
            },
            "therapy": {
                "id": 3960,
                "therapyName": "Palbociclib + PF-04691502",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14836,
                    "pubMedId": 30647837,
                    "title": "CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30647837"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16759,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Afinitor (everolimus) synergisticaly inhibited growth of Cdkn2a-null non-small cell lung cancer cell lines in culture (PMID: 30647837).",
            "molecularProfile": {
                "id": 27380,
                "profileName": "CDKN2A negative"
            },
            "therapy": {
                "id": 3958,
                "therapyName": "Everolimus + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14836,
                    "pubMedId": 30647837,
                    "title": "CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30647837"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16758,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ibrance (palbociclib) treatment resulted in no objective response (0/16) and stable disease in 50% (8/16) of patients with advanced Cdkn2a-null (by IHC) non-small cell lung cancer, with a median overall survival (mOS) of 5.1 months for all patients and a mOS of 16.6 months in patients achieved stable disease (PMID: 30647837; NCT01291017).",
            "molecularProfile": {
                "id": 27380,
                "profileName": "CDKN2A negative"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14836,
                    "pubMedId": 30647837,
                    "title": "CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30647837"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16760,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Rapamune (sirolimus) synergisticaly inhibited growth of Cdkn2a-null non-small cell lung cancer cell lines in culture (PMID: 30647837).",
            "molecularProfile": {
                "id": 27380,
                "profileName": "CDKN2A negative"
            },
            "therapy": {
                "id": 4130,
                "therapyName": "Palbociclib + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14836,
                    "pubMedId": 30647837,
                    "title": "CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30647837"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27380,
            "profileName": "CDKN2A negative",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}